 2. Combination therapy with ipilimumab YERVOY, anti-CTLA-4 - for patients with PD-L1 and PD-L2 negative tumors defined as at less than 1 of tumor cells on biopsy or archival material, or 1 of circulating tumor cells, staining positive for PD-L1 or PD-L2. 